Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Geodon(Ziprasidone Mesylate)

Medicare prescription drug cost, prescriptions and prescribers, 2024

$25K

Medicare cost, 2024

Medicare drug plans spent $24,547 on Geodon (ziprasidone mesylate) in 2024, for 129 prescriptions and refills filled by 44 patients. Spending rose 18% from 2023 to 2024.

Medicare cost, 2024

$25K

+17.7% from 2023

Prescriptions

129

$190.28 per claim

Patients

44

52 prescribers

Total spending, 2024

$25K

$557.88 per patient

Questions and answers

How much does Medicare spend on Geodon?

Medicare prescription drug plans paid $25K for Geodon in 2024, for 129 prescriptions and refills to 44 patients (up 17.7% from 2023). The average cost per claim was $190.28.

Which state spends the most on Geodon?

Georgia had the highest Medicare cost for Geodon in 2024: $9,117 for 26 claims, followed by Texas ($5,134).

Who prescribes Geodon the most?

Clyde O Green, family practice in Macon, GA, had the highest Medicare cost for Geodon in 2024: 18 claims costing $6,358.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Geodon was $25K in 2024, after a high of $508K in 2020.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Geodon, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Clyde O Green Macon, GAFamily Practice18Under 11$6,358
Christopher N Mancha El Paso, TXNurse Practitioner11Under 11$957

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022131260171$53K
20237311679$21K
20245212944$25K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Pfizer/Viatris129$25K

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube